Filament BioSolutions and Ajinomoto North America have formed a partnership to develop and commercialize a portfolio of medical foods. Through the partnership, Filament has received financing from Ajinomoto, and will work closely with Ajinomoto’s scientists and food technologists to assist in product development, as well as to identify future opportunities for additional medical food products.

Filament has introduced two medical food product candidates into its portfolio, FB-2710 and FB-3100. Both candidates will incorporate Ajinomoto amino acids that will be formulated to address specific underlying nutritional deficiencies, resulting from a disease, in patients that are under the supervision of a physician.

“We are currently in an exciting time for the pharmaceutical, food and nutrition industries as they are merging to create a new category of science-based nutritional products,” said Thomas Cirrito, founder and chief executive officer, Filament BioSolutions. “This collaboration between Filament and Ajinomoto is the result of a shared vision to lead the medical food industry as we shift the clinical treatment paradigm towards addressing nutritional deficiencies as a key component of underlying disease states in order to improve patient care. We believe there is a major gap in the healthcare system that we are addressing by creating evidence-based nutritional therapies.”

Tatsuya Sato, president and chief operating officer, Ajinomoto North America said, “We believe this collaboration demonstrates the synergy between Ajinomoto’s 100-year history as a global leader in amino acid production and the Filament team’s innovative approach of translating our amino acid technology into the medical nutrition space. We look forward to working with Filament in the creation of the next generation of nutritional products to improve patient health.”